Paper42663506
Inhibition of miR-301a-3p Expression Promotes Ferroptosis: A New Target for Ferroptosis Treatment in TNBC.
Fu B and 5 others. Breast J, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Inhibition of miR-301a-3p Expression Promotes Ferroptosis: A New Target for Ferroptosis Treatment in TNBC. Papers, record 42663506. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42663506
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Inhibition of miR-301a-3p Expression Promotes Ferroptosis: A New Target for Ferroptosis Treatment in TNBC.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| MicroRNAs | Major topic |
| Ferroptosis | Major topic |
| Triple Negative Breast Neoplasms | Major topic |
| Humans | |
| Female | |
| Cell Proliferation | |
| Cell Line, Tumor | |
| Gene Expression Regulation, Neoplastic | |
| Phospholipid Hydroperoxide Glutathione Peroxidase | |
| Reactive Oxygen Species | |
| Cell Movement | |
| Piperazines | |
| Prognosis |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| 81972469 | National Natural Science Foundation of China | PubMed | PubMed | ||
| YJSCX2025-58HYD | Harbin Medical University | YJSCX202558 | PubMed | NIH RePORTER |
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32106859 | CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. | Mol Cancer | 2020 | https://conductscience.org/library/papers/32106859 | PubMed |
| 2 | 42663506 | Inhibition of miR-301a-3p Expression Promotes Ferroptosis: A New Target for Ferroptosis Treatment in TNBC. | Breast J | 2026 | https://conductscience.org/library/papers/42663506 | PubMed |
| 3 | 36938678 | LINC00460 Facilitates Cell Proliferation and Inhibits Ferroptosis in Breast Cancer Through the miR-320a/MAL2 Axis. | Technol Cancer Res Treat | 2023 | https://conductscience.org/library/papers/36938678 | PubMed |
| 4 | 34668628 | CircGFRA1 facilitates the malignant progression of HER-2-positive breast cancer via acting as a sponge of miR-1228 and enhancing AIFM2 expression. | J Cell Mol Med | 2021 | https://conductscience.org/library/papers/34668628 | PubMed |
| 5 | 36408273 | Relationship between miRNA and ferroptosis in tumors. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/36408273 | PubMed |
| 6 | 35741721 | The History of Early Breast Cancer Treatment. | Genes (Basel) | 2022 | https://conductscience.org/library/papers/35741721 | PubMed |
| 7 | 36613888 | Lipid Peroxidation and Iron Metabolism: Two Corner Stones in the Homeostasis Control of Ferroptosis. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36613888 | PubMed |
| 8 | 32970954 | MicroRNA (MiR)-301a-3p regulates the proliferation of esophageal squamous cells via targeting PTEN. | Bioengineered | 2020 | https://conductscience.org/library/papers/32970954 | PubMed |
| 9 | 37700851 | TMEM189 as a target gene of MiR-499a-5p regulates breast cancer progression through the ferroptosis pathway. | J Clin Biochem Nutr | 2023 | https://conductscience.org/library/papers/37700851 | PubMed |
| 10 | 36257316 | Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. | Cell Metab | 2023 | https://conductscience.org/library/papers/36257316 | PubMed |
| 11 | 33522578 | Metformin induces ferroptosis by targeting miR-324-3p/GPX4 axis in breast cancer. | Acta Biochim Biophys Sin (Shanghai) | 2021 | https://conductscience.org/library/papers/33522578 | PubMed |
| 12 | 30322806 | MicroRNA-301a-3p suppressed the progression of hepatocellular carcinoma via targeting VGLL4. | Pathol Res Pract | 2018 | https://conductscience.org/library/papers/30322806 | PubMed |
| 13 | 37591453 | FOXQ1 inhibits breast cancer ferroptosis and progression via the circ_0000643/miR-153/SLC7A11 axis. | Exp Cell Res | 2023 | https://conductscience.org/library/papers/37591453 | PubMed |
| 14 | 26640587 | Hsa-miR-301a-3p Acts as an Oncogene in Laryngeal Squamous Cell Carcinoma via Target Regulation of Smad4. | J Cancer | 2015 | https://conductscience.org/library/papers/26640587 | PubMed |
| 15 | 36038913 | Recent advances in therapeutic strategies for triple-negative breast cancer. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/36038913 | PubMed |
| 16 | 34754128 | Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. | Nat Rev Clin Oncol | 2022 | https://conductscience.org/library/papers/34754128 | PubMed |
| 17 | 34571083 | SLC7A11/ xCT is a target of miR-5096 and its restoration partially rescues miR-5096-mediated ferroptosis and anti-tumor effects in human breast cancer cells. | Cancer Lett | 2021 | https://conductscience.org/library/papers/34571083 | PubMed |
| 18 | 32789480 | Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial. | JAMA Oncol | 2020 | https://conductscience.org/library/papers/32789480 | PubMed |
| 19 | 31762806 | Cip2a/miR-301a feedback loop promotes cell proliferation and invasion of triple-negative breast cancer. | J Cancer | 2019 | https://conductscience.org/library/papers/31762806 | PubMed |
| 20 | 26019136 | MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4. | Oncotarget | 2015 | https://conductscience.org/library/papers/26019136 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 42663506 | Inhibition of miR-301a-3p Expression Promotes Ferroptosis: A New Target for Ferroptosis Treatment in TNBC. | Breast J | 2026 | https://conductscience.org/library/papers/42663506 |
Source PubMed
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| GPX4 | 2879 | PubTator's text mining | https://conductscience.org/library/genes/2879 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42663506
GET https://conductscience.org/api/papers/v1/42663506/references?page=2